Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2625

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

This text presents information on the proportion of patients who relapsed over time for the placebo and duloxetine treatments. The data is displayed graphically with time (in days) on the X-axis and the proportion of patients on the Y-axis. The Kaplan-Meier estimator method was used for analysis. The chart shows a decreasing trend in the relapse rate over the observed period for both treatments.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

This text provides data on the proportion of patients experiencing a relapse over time while being treated with either Placebo or Duloxetine. The numbers indicate the number of patients experiencing relapse at different time points after randomization. The data is likely presented using the Kaplan-Meier estimator method.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

This text provides information on the percentage of patients showing improvement in pain levels when taking different doses of duloxetine and placebo. The data seems to compare the efficacy of Duloxetine 60mg, Duloxetine 20mg, and placebo in managing pain. The percentage of patients improved can help evaluate the effectiveness of these medications in pain relief.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

Percentage of Patients Improved with Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and Placebo treatment. Improvement in pain from baseline is also shown.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

The text provides information on the percentage of patients improved with different treatments for pain management. It shows the comparison between Duloxetine 120mg twice daily, Duloxetine 60mg once daily, and a Placebo. The percentage of improvement in pain from the baseline is also represented in the data.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

This text provides information on the percentage of patients improved with a placebo compared to duloxetine 60/120 mg once daily. It includes a data chart showing the percent improvement in pain from baseline.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

This text provides data on the percentage of patients improved with the use of Duloxetine 60 mg compared to a placebo. It indicates that 100% of patients showed improvement with Duloxetine 60 mg compared to the placebo. The graph shows the percent improvement in pain from baseline over time with treatments.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

This text mentions the percentage of patients improved with Duloxetine 60/120 mg compared to a placebo, with a potential improvement of 100%. It also indicates the percent improvement in pain from baseline (BOCF). This data can be helpful for understanding the efficacy of Duloxetine in treating certain conditions.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

FDA Label Image

Label (Lbl713352625)

The text provides information about a delayed-release capsule containing 67.3 mg of Duloxetine Hydrochloride USP, equivalent to 60 mg NDC 71335-2625_1. It suggests checking the package insert QR code for prescribing information and advises storing the capsules at 25°C with excursions permitted to 15° to 30°C. The text also mentions keeping the medication out of reach of children and instructs to dispense in a tightly closed container. Manufacturer information includes Bryant Ranch Prepack, Inc. and Lupin Limited.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.